Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592851 · ClinicalTrials.gov registry record · Phase 3
Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 113
- Enrollment target
NCT01592851 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 113 participants.
The verdict
NCT01592851, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 113 participants
- Enrollment target
Study Summary
A study to compare the efficacy of a test dentifrice against a control dentifrice in reducing dentinal hypersensitivity over a two week treatment period.
Interventions
- DRUG Stannous Fluoride
- DRUG Sodium Monofluorophosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592851
The ClinicalTrials.gov registry entry for NCT01592851 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stannous Fluoride is the first listed.
NCT01592851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592851 about?
NCT01592851 is a clinical study titled "Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity". A study to compare the efficacy of a test dentifrice against a control dentifrice in reducing dentinal hypersensitivity over a two week treatment period.
What is the current status of trial NCT01592851?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 113 participants. The study started on 2012-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01592851?
The interventions under investigation include: Stannous Fluoride (DRUG), Sodium Monofluorophosphate (DRUG).
Who is sponsoring clinical trial NCT01592851?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.